At A Glance

illumina®

Who we are

As a global leader in DNA sequencing and microarray-based solutions, we are dedicated to improving human health by unlocking the power of the genome. Our technology is responsible for generating more than 90% of the world's sequencing data.[1]

Quick facts

$3.3 Billion (2018)
Annual revenue

>7,300
Number of employees

Francis deSouza
President & CEO

San Diego, California, USA
Headquarters

1998
Year founded

Who we serve

We serve customers in a broad range of research, clinical, and applied markets, including:

Oncology	Reproductive health	Genetic disease	Microbiology	Agriculture	Molecular & cell biology

We enable the adoption of genomic solutions in settings such as:

Universities and academic research centers	Pharmaceutical companies	Genome centers	Biotechnology companies	Hospitals	Consumer genetics companies	Government agencies

Where we operate



United States
San Diego (Headquarters)
Foster City
Hayward
Madison

Brazil
São Paulo

United Kingdom
Cambridge

France
Évry

Germany
Berlin

Netherlands
Eindhoven

China
Beijing
Shanghai

Japan
Tokyo
Osaka

Singapore

Australia
Melbourne

South Korea
Seoul

Making breakthroughs possible

Illumina has developed one of the world's most comprehensive genomics portfolio of integrated systems, consumables, and analysis tools. With each technological breakthrough, we help scientists better understand genetic variation at all levels of complexity.

Sequencing systems

NovaSeq™ 6000

High-throughput sequencing for any species, application, or scale of sequencing project, including genomes, exome, and transcriptomes.

NextSeq™ 550

Benchtop sequencer for genome sequencing, exome sequencing, transcriptome sequencing and cytogenomic and methylation array scanning.

MiSeq™

Benchtop sequencer for targeted and small-genome sequencing.

MiniSeq™

Benchtop sequencer for targeted DNA and targeted RNA sequencing.

NextSeq™ 550Dx*

Benchtop IVD sequencer for comprehensive cancer testing and NIPT, as well as clinical research applications, from targeted panels to exomes; cleared or approved in > 20 countries.

MiSeq™ Dx*

Benchtop IVD sequencer for targeted tumor profiling and genetic disease testing, as well as clinical research applications including amplicon sequencing; cleared or approved in > 20 countries.

Array scanners

iSeq™ 100

Benchtop sequencer for targeted gene sequencing, direct amplicon sequencing, and small-genome sequencing.

iScan™ System

Genotyping, CNV analysis, DNA methylation, and gene expression profiling.

Cost of sequencing, per human whole genome



Since 2001, the cost of DNA sequencing has dropped more than 100,000x from $100 million per human genome to less than $1,000 today. Discoveries that were unimaginable a few years ago are now becoming routine.

A recognized leader

Top CEOs
Glassdoor 2018 (#44)

World's Most Innovative Companies List
Forbes 2014 (#36)
Forbes 2015 (#35)
Forbes 2016 (#24)
Forbes 2017 (#18)
Forbes 2018 (#20)

10 Most Innovative Biotech Companies
Fast Company 2016, 2017

50 Smartest Companies
MIT Technology Review
2014 (#1), 2015 (#3),
2016 (#3), 2017 (#22)

10 Breakthrough Technologies 2013
MIT Technology Review 2013

Best Places to Work
2019 Glassdoor Employees' Choice Best Place to Work (#33)
2018 Forbes America's Best Midsize Employers (#142 of 500)

Fastest-Growing Tech Companies
Fortune 2016
Fortune Future 50 2018 (#36)

*For *In Vitro* Diagnostic Use.

For Research Use Only (except as specifically noted). Not for use in diagnostic procedures.

References
1. Data calculations on file. Illumina, Inc., 2017
2. Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). Available at: www.genome.gov/sequencingcosts
3. NovaSeq™ 6000 Sequencing System

illumina®